Justice Department eases restrictions on some marijuana products - CBS News
The Justice Department has eased restrictions on some marijuana products, potentially rescheduling cannabis from Schedule I to Schedule III under the Controlled Substances Act. This change affects DEA quotas, research protocols, and compliance for pharmaceutical manufacturers handling cannabis-derived substances.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Pharmaceutical manufacturers, including branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) that produce or handle cannabis-derived products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate review; formal compliance updates within 30 days of official rule publication.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The Justice Department announced a policy shift to ease restrictions on certain marijuana products, likely moving them from Schedule I to Schedule III. This reduces DEA quota requirements and alters cGMP and DSCSA compliance obligations for cannabis-derived drugs.
Who it affects
Pharmaceutical manufacturers, including branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) that produce or handle cannabis-derived products.
What you must do
Review current product portfolios for cannabis-derived substances; assess impact on DEA registrations, quotas, and supply chain tracking; update SOPs and training to align with new scheduling.
Deadline
Immediate review; formal compliance updates within 30 days of official rule publication.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Experimental Drugs Without FDA Approval Are Now Legal in Montana - VICE
- Feds give 2-year approval to Florida’s Canadian prescription drug importation plan - Florida Politics
- GLP‑1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters - JD Supra
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag